IGF2BP2 and thyroid gland carcinoma: MALAT1 promotes thyroid cancer progression by binding to miR-204 and upregulating IGF2BP2, thereby affecting miR-204/IGF2BP2/m6A-MYC signaling (Ye et al., 2021).